The activities of two metalloproteinases, MMP-2 and MMP-9, were studied in the primary WM3211 and metastatic Mel-1359 and MEWO melanoma cell lines after 24 h and 48 h treatment with mTOR inhibitors and their combinations. The gene discussed is MMP9; the disease is melanoma.